Vammen, Lauge
Johannsen, Cecilie Munch
Magnussen, Andreas
Povlsen, Amalie
Petersen, Søren Riis
Azizi, Arezo
Pedersen, Michael
Korshøj, Anders Rosendal
Ringgaard, Steffen
Løfgren, Bo
Andersen, Lars W.
Granfeldt, Asger http://orcid.org/0000-0002-7241-6131
Funding for this research was provided by:
Sundhed og Sygdom, Det Frie Forskningsråd
Sundhedsvidenskabelige Fakultet, Aarhus Universitet
Riisfort Fonden
Augustinus Fonden
Familien Hede Nielsens Fond
Sundhed, Region Midtjylland
Article History
Received: 3 August 2022
Accepted: 17 October 2022
First Online: 26 October 2022
Declarations
:
: The study was approved by the Danish Animal Experiments Inspectorate (License number: 2019-15-0201-01647) and conducted and reported in accordance with the ARRIVE [CitationRef removed] guidelines.
: Not applicable.
: AG reported receiving personal fees from Noorik Biopharmaceuticals outside the submitted work. Furthermore AG is co-inventor on a patent owned by Aarhus University claiming the use of senicapoc for ARDS caused by COVID-19. Other authors have none to declare.